Technetium Tc 99m tilmanocept fails to detect sentinel lymph nodes in endometrial cancer.

ABSTRACT:

Background

Technetium Tc 99m tilmanocept is a synthetic radiotracer specifically designed for sentinel lymph node (SLN) mapping that has been FDA-approved in breast cancer, melanoma, and head and neck cancer. No published studies exist for the use of this radiotracer in endometrial cancer.

Objective

The primary objective was to determine the detection rate of bilateral SLNs in endometrial cancer with the concurrent use of technetium Tc 99m tilmanocept and ICG.

Methods

An open-label, single cohort, prospective feasibility study was conducted with participants receiving preoperative cervical injections of technetium Tc 99m tilmanocept followed by subsequent imaging and SPECT/CT. Intraoperative ICG injections were administered for all patients with near-infrared imaging

SUBMITTER: Reddy RA 

PROVIDER: S-EPMC9361318 | biostudies-literature | 2022 Oct

REPOSITORIES: biostudies-literature